// App-Quantinova.ai

: Efficacy and Safety of Idarucizumab for Rapid Reversal from Dabigatran in Patients Undergoing Orthotopic Heart Transplantation

Researchers

Presenter

  • I. Kim

Principal Investigators

  • H. Kim

  • W. Chang

  • J. Kim

  • N. Park

  • J. Youn

  • S. Choi

  • S. Jun

  • Y. Cho

  • H. Yoon

  • C. Nam

  • S. Han

  • S. Hur

  • H. Park

Medical Centers

  • Keimyung University Dongsan Medical Center, Daegu, Korea

  • Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Daegu, Republic of Korea

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Arrhythmia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Idarucizumab

  • Pradax

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved